Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17712316 | 1.00 | TMPRSS2 (0.39) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL17712512 | 1.00 | TMPRSS2 (0.39) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL18309986 | 1.00 | TMPRSS2 (0.39) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL18309987 | 0.99 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL17712519 | 0.99 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL17712257 | 0.99 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL17712262 | 0.98 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL24462486 | 0.98 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL17712260 | 0.98 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL24148739 | 0.94 | TMPRSS2 (0.39) | TMPRSS2CYP3A4CYP2C9RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | TMPRSS2 14/4885CYP3A4 1181/4885CYP2C9 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.